异位性皮肤炎市场：现况分析与预测（2023-2030）

Atopic Dermatitis Market: Current Analysis and Forecast (2023-2030)

出版日期: 2024年02月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 158 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

预计 2023 年至 2030 年异位性皮肤炎市场的复合年增长率约为 11.2%。异位性皮肤炎（AD），也称为湿疹，是一种以发红、搔痒和发炎为特征的慢性发炎性皮肤病。它通常开始于婴儿期或儿童期，但可能持续到成年期。 AD被认为是遗传、免疫和环境因素综合作用的结果，包括皮肤屏障缺陷、免疫系统失调以及接触过敏原和刺激物。异位性皮肤炎是一种广泛存在的慢性发炎性皮肤病，其盛行率在全球范围内不断增加，特别是在已开发国家，推动了异位性皮肤炎（AD）市场的发展。例如，根据世界过敏组织 (WAO) 的数据，儿童 AD 盛行率为 15% 至 30%，成人为 2% 至 10%。此外，全球医疗保健支出的增加使患者能够更好地获得医疗保健服务和异位性皮肤炎等慢性疾病的治疗。例如，根据《JAMA Dermatology》发表的一项研究，2018 年美国异位性皮肤炎的年度费用超过 53 亿美元，其中大部分费用来自处方药和门诊。

依药物类别，市场分为皮质类固醇、PDE4 抑制剂、钙调神经磷酸酶抑制剂、皮肤屏障润肤剂等。其中，皮质类固醇已被证明可有效控制与 AD 相关的发炎和搔痒，且与一些新疗法相比应用广泛，且价格相对便宜，预计市场复合年增长率较高。皮质类固醇，无论是局部使用还是全身使用，长期以来一直是治疗 AD 的主要药物，有助于快速缓解症状并限制病情发作。因此，它仍然是医疗保健提供者和患者中治疗轻度至中度 AD 以及作为严重病例的辅助治疗的热门选择。

根据最终用户，市场分为医院药房、零售药房和线上药房。特别是，预计在预测期内，医院药局将越来越多地采用异位性皮肤炎药。由于多种因素，包括异位性皮肤炎(AD) 盛行率的增加、新治疗方案的出现以及医院环境中对专业护理的需求不断增长，医院药房部门见证了特应性皮肤炎(AD) 市场的增长。医院在 AD 治疗中发挥重要作用，特别是在需要重症监护、多学科护理和先进治疗的严重病例中。製药公司不断开发和推出新的 AD 治疗方法，包括生物製剂、小分子抑制剂和新型外用药物。此外，医院药局可能会提供专门的复方药物调配服务，以满足 AD 患者的独特需求。

为了更瞭解异位性皮肤炎产业的市场实施情况，市场包括北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、义大利、欧洲其他地区）、亚太地区（中国、日本、印度、亚太地区其他地区）和世界其他地区。由于异位性湿疹盛行率不断增加、一般人群对异位性皮肤炎的认识不断增强以及生活方式的改变，北美异位性皮肤炎市场预计将继续增长。例如，根据 eczema.org 的数据，到 2020 年，美国将有 3,160 万人（10.1%）患有某种形式的湿疹，盛行率在儿童早期达到高峰。据估计，十分之一的人在一生中会患上湿疹，患病率在儿童早期达到高峰。

The Atopic Dermatitis market is expected to register a CAGR of approx. 11.2% over the period of 2023-2030. Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory skin condition characterized by red, itchy, and inflamed patches of skin. It is a common condition that typically begins in infancy or childhood but can persist into adulthood. AD is believed to result from a combination of genetic, immune, and environmental factors, including defects in the skin barrier, immune system dysregulation, and exposure to allergens or irritants. Atopic dermatitis is a widespread chronic inflammatory skin condition, with its prevalence increasing globally, particularly in industrialized nations is boosting the atopic dermatitis(AD) market. For instance, According to the World Allergy Organization (WAO), AD prevalence ranges from 15% to 30% in children and 2% to 10% in adults globally. Moreover, with increasing healthcare expenditure worldwide, patients have greater access to healthcare services and treatments for chronic conditions like atopic dermatitis. For instance, According to a study published in JAMA Dermatology, the annual cost of atopic dermatitis in the United States exceeded $5.3 billion in 2018, with the majority of costs attributed to prescription medications and outpatient visits.

Based on the Drug Class, the market has been categorized into corticosteroids, pde4 inhibitors, calcineurin inhibitors, skin barrier emollients, others. Among them, the corticosteroids segment is expected to grow at a higher CAGR in the market due to several factors, including its well-established efficacy in managing inflammation and itching associated with AD, its widespread availability, and its relatively low cost compared to some newer treatment options. Corticosteroids, whether topical or systemic, have long been a mainstay in the treatment of AD, offering rapid relief of symptoms and helping to control flare-ups. As a result, they remain a popular choice among healthcare providers and patients for the management of mild to moderate AD and as adjunctive therapy in more severe cases.

Based on the end-user, the market has been categorized into hospital pharmacies, retail pharmacies, online pharmacies. Among them, the hospital pharmacies category is to witness higher adoption of atopic dermatitis during the forecast period. The hospital pharmacy segment is experiencing growth in the atopic dermatitis (AD) market due to several factors, including the increasing prevalence of AD, the emergence of new treatment options, and the rising demand for specialized care in hospital settings. Hospitals play a crucial role in the management of AD, particularly in cases of severe disease requiring intensive therapy, multidisciplinary care, or access to advanced treatment modalities. Pharmaceutical companies continue to develop and introduce new treatment options for AD, including biologics, small molecule inhibitors, and novel topical formulations. Moreover, hospital pharmacies may offer specialized compounding services to tailor medications to the specific needs of AD patients.

For a better understanding of the market adoption of the Atopic Dermatitis industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North America atopic dermatitis market is expected to continue to grow in the coming years, driven by the increasing prevalence of atopic eczema and growing awareness of atopic dermatitis among the general population, change in lifestyle. For instance, in 2020, according to national eczema.org, 31.6 million people (10.1%) in the U.S. have some form of eczema, and prevalence peaks during early childhood. It is estimated that 1 in 10 individuals will develop eczema during their lifetime, with prevalence peaking in early childhood.

Some of the major players operating in the market include Pfizer Inc., Abbvie Inc., Bristol Myers Squibb, Regeneron Pharmaceuticals, Inc., Evelo Biosciences, Inc., Sanofi, Novartis AG, GALDERMA LABORATORIES, L.P., Eli Lilly and Company (Dermira), Otsuka Pharmaceutical Co., Ltd.

1. MARKET INTRODUCTION

1.1.Market Definitions
1.2.Main Objective
1.3.Stakeholders
1.4.Limitation

2. RESEARCH METHODOLOGY OR ASSUMPTION

2.1.Research Process of the Atopic Dermatitis Market
2.2.Research Methodology of the Atopic Dermatitis Market
2.4.Respondent Profile

3. MARKET SYNOPSIS

4. EXECUTIVE SUMMARY

5. IMPACT OF COVID-19 ON THE ATOPIC DERMATITIS MARKET

6. GLOBAL ATOPIC DERMATITIS MARKET REVENUE, 2020-2030F

7. MARKET INSIGHTS BY DRUG CLASS

7.1.Corticosteroids
7.2.PDE4 Inhibitors
7.3.Calcineurin Inhibitors
7.4.Skin Barrier Emollients
7.5.Others

8. MARKET INSIGHTS BY END USER

8.1.Hospital Pharmacies
8.2.Retail Pharmacies
8.3.Online Pharmacies

9. MARKET INSIGHTS BY REGION

9.1NORTH AMERICA ATOPIC DERMATITIS MARKET
- 9.1.1.U.S.
- 9.1.2.Canada
- 9.1.3.Rest of North America
9.2EUROPE ATOPIC DERMATITIS MARKET
- 9.2.1.Germany
- 9.2.2.U.K.
- 9.2.3.France
- 9.2.4.Italy
- 9.2.5.Spain
- 9.2.6.Rest of Europe
9.3ASIA PACIFIC ATOPIC DERMATITIS MARKET
- 9.3.1.China
- 9.3.2.Japan
- 9.3.3.India
- 9.3.4.Rest of Asia-Pacific
9.4REST OF THE WORLD ATOPIC DERMATITIS MARKET